期刊
HUMAN IMMUNOLOGY
卷 82, 期 11, 页码 850-858出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2021.07.006
关键词
Transplantation; Rejection; Cell free DNA; DNA sequencing; Biomarker
类别
Using NGS to interrogate cfDNA improves accuracy in post-transplant monitoring, revealing mechanisms of injury. Monitoring donor-derived cfDNA aids in identifying allograft injury and rejection, providing minimally invasive, quantitative measures across organ types.
The use of Next Generation Sequencing (NGS) to interrogate cell-free DNA (cfDNA) as a transplant diag-nostic provides a crucial step in improving the accuracy of post-transplant monitoring of allograft health. cfDNA interrogation provides a powerful, yet minimally invasive, biomarker for disease and tissue injury. cfDNA can be isolated from a variety of body fluids and analyzed using bioinformatics to unlock its ori-gins. Furthermore, cfDNA characteristics can reveal the mechanisms and conditions under which it was generated and released. In transplantation, donor-derived cfDNA monitoring provides a tool for identify-ing active allograft injury at the time of transplant, infection, and rejection. Multiple detection and inter-rogation methods for cfDNA detection are now being evaluated for clinical validity and hold the promise to provide minimally invasive, quantitative, and reproducible measures of allograft injury across organ types. (c) 2021 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据